Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

d the business combination with Transave on December 1, 2010.  The improved return on investments reflected the increased cash position and higher yield rates, while the lower interest expense was due to the elimination of the debt discount amortization.

As of December 31, 2010, Insmed had total cash, cash equivalents, short-term investments, and certificate of deposits on hand of $110.2 million, consisting of $108.0 million in cash and short-term investments and $2.2 million in a certificate of deposit, as compared to $124.3 million of cash on hand as of December 31, 2009.  The $14.1 million decrease in total cash was due to the $8.0 million full payment of Transave debt at the time of the merger, together with the payment of approximately $6.1 million in costs primarily related to the strategic review during 2010 and the business combination with Transave.

Conference CallTo participate in today's live conference call, please dial 866-543-6405 (U.S. callers) or 617-213-8897 (international), and provide passcode 84436520.  A live webcast of the call will also be available at: http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=3766623.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.  The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on March 10th 2011, at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 46156189.

About InsmedInsmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmed's primary focus is on the development of inhaled
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Insmed to Host Second Quarter 2009 Conference Call
2. Insmed Announces Addition to the Russell 3000(R) Index
3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
4. Insmed CEO Resigns Due to Health Concerns
5. Insmed Announces First Quarter 2009 Financial Results
6. Insmed Regains NASDAQ Compliance
7. Insmed to Host First Quarter 2009 Conference Call
8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... VIEW, Calif., Nov. 7, 2011 VIVUS, Inc. (NASDAQ: ... and commercialization of novel therapeutic products, today reported its financial ... 30, 2011. Third Quarter ResultsFor the ... loss of $8.6 million, or $0.10 net loss per share, ...
... November 7, 2011 Note: numbers in square ... Boulter is available for interview. Investment fund manager ... today won a court battle with 3M over the multi-national ... The High Court in London found 3M was ...
... HANOVER, N.J., Nov. 7, 2011 Novartis announced today ... with active systemic juvenile idiopathic arthritis (SJIA) were able ... described as steroids) within 28 weeks of commencing treatment ... of the study, which met both primary endpoints, will ...
Cached Biology Technology:VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 2VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 3VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 4VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 5VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 6VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 7VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 8VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 93M Forced to Pay for Breach of Obligations Over MRSA - High Court 23M Forced to Pay for Breach of Obligations Over MRSA - High Court 33M Forced to Pay for Breach of Obligations Over MRSA - High Court 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 2Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 3Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 5Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 6Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 7
(Date:4/17/2014)... MANHATTAN, KAN. A Kansas State University engineer ... security and remotely detects improvised explosive devices. The ... , William Dunn, the Steven M. and Kay ... of mechanical and nuclear engineering, and his research ... explosives hidden underground or in car trunks. The ...
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... 2012 Chiltern International Limited (Chiltern), a global contract ... James Gunter have joined Chiltern, bringing their expertise in ... strengthen our Global Clinical Development services. ... Cedric Burg has been appointed to the position of ...
... pests by using ultrasonic frequencies are available and marketed ... been demonstrated as being effective in repelling insect pests ... of evidence for the efficacy of such devices, they ... bugs are readily available. However, according to a ...
... reprogramming a 7-year-old girl,s own immune cells to attack ... has achieved a complete response in his patient, who ... The innovative experimental therapy used bioengineered T cells, custom-designed ... leukemia cells. After the treatment, the child,s doctors found ...
Cached Biology News:Chiltern Welcomes Cedric Burg And James Gunter 2Engineered immune cells produce complete response in child with an aggressive pediatric leukemia 2Engineered immune cells produce complete response in child with an aggressive pediatric leukemia 3
... cultured in DMEM with 4 mM L-glutamine medium ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
... P815 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
...
Biology Products: